[{"id":"ac72e48c-1524-449b-acbb-64797b142680","acronym":"","url":"https://clinicaltrials.gov/study/NCT04965597","created_at":"2021-07-16T13:53:25.569Z","updated_at":"2025-02-25T16:32:32.043Z","phase":"Phase 2","brief_title":"Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)","source_id_and_acronym":"NCT04965597","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C","pipe":" | ","alterations":" LDH elevation","tags":["HLA-DRB1 • HLA-DQB1 • GATA2 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e LDH elevation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 04/19/2022","start_date":" 04/19/2022","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2025-02-07"},{"id":"91e34a00-0291-46e3-8305-1607660e8c78","acronym":"","url":"https://clinicaltrials.gov/study/NCT04994808","created_at":"2021-08-06T12:53:07.543Z","updated_at":"2025-02-25T16:45:30.587Z","phase":"Phase 2","brief_title":"Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia","source_id_and_acronym":"NCT04994808","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e clofarabine • fludarabine IV • busulfan • Grafapex (treosulfan)"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 08/11/2023","start_date":" 08/11/2023","primary_txt":" Primary completion: 10/03/2026","primary_completion_date":" 10/03/2026","study_txt":" Completion: 04/03/2027","study_completion_date":" 04/03/2027","last_update_posted":"2025-02-05"},{"id":"d7ed8a2f-8937-4cbd-aa4d-ea29935f9c24","acronym":"","url":"https://clinicaltrials.gov/study/NCT04195633","created_at":"2021-01-18T20:26:55.926Z","updated_at":"2024-07-02T16:35:01.612Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies","source_id_and_acronym":"NCT04195633","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • busulfan • Grafapex (treosulfan) • Neupogen (filgrastim) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 01/25/2021","start_date":" 01/25/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2024-05-23"},{"id":"3b52b9d4-20d4-4a79-a816-f21eb9b91b3d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05807932","created_at":"2023-04-11T14:03:36.196Z","updated_at":"2024-07-02T16:35:06.548Z","phase":"Phase 1/2","brief_title":"Venetoclax in Addition to Sequential Conditioning With Fludarabine / Amsacrine / Ara-C (FLAMSA) + Treosulfan for Allogeneic Blood Stem Cell Transplantation in Patients With MDS, CMML or sAML","source_id_and_acronym":"NCT05807932","lead_sponsor":"Heinrich-Heine University, Duesseldorf","biomarkers":" KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation","tags":["KRAS • TP53 • NRAS • IDH1 • IDH2 • NF1 • RUNX1 • KMT2A • PTPN11 • NUP214 • DEK • RIT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • NF1 mutation • RAS mutation • CBL mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • fludarabine IV • Grafapex (treosulfan) • Amsidine (amsacrine)"],"overall_status":"Recruiting","enrollment":" Enrollment 38","initiation":"Initiation: 06/26/2023","start_date":" 06/26/2023","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/30/2028","study_completion_date":" 01/30/2028","last_update_posted":"2024-05-01"},{"id":"1edc78b4-0777-46be-b8be-5e59595927a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT05534620","created_at":"2022-09-09T15:55:12.704Z","updated_at":"2024-07-02T16:35:18.473Z","phase":"Phase 1","brief_title":"Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics","source_id_and_acronym":"NCT05534620","lead_sponsor":"medac GmbH","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Grafapex (treosulfan)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/01/2024","start_date":" 02/01/2024","primary_txt":" Primary completion: 08/01/2025","primary_completion_date":" 08/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-02-21"},{"id":"c82699ae-b7c6-4286-82ae-9872dcf1d86b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03980769","created_at":"2021-01-18T19:34:51.355Z","updated_at":"2024-07-02T16:35:20.972Z","phase":"Phase 2","brief_title":"Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders","source_id_and_acronym":"NCT03980769","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • CD34 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • thiotepa • busulfan • Grafapex (treosulfan)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 05/05/2021","start_date":" 05/05/2021","primary_txt":" Primary completion: 07/01/2027","primary_completion_date":" 07/01/2027","study_txt":" Completion: 07/01/2027","study_completion_date":" 07/01/2027","last_update_posted":"2024-02-05"},{"id":"738fa48d-f8a9-4706-a089-656371dd06cc","acronym":"","url":"https://clinicaltrials.gov/study/NCT01063647","created_at":"2021-01-18T04:11:24.649Z","updated_at":"2024-07-02T16:35:30.505Z","phase":"Phase 2","brief_title":"Dose-range Finding Treosulfan-based Conditioning","source_id_and_acronym":"NCT01063647","lead_sponsor":"medac GmbH","biomarkers":" ABL1 • BCR • HLA-DRB1","pipe":" | ","alterations":" Chr del(5q)","tags":["ABL1 • BCR • HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Chr del(5q)"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Grafapex (treosulfan)"],"overall_status":"Completed","enrollment":" Enrollment 56","initiation":"Initiation: 11/01/2001","start_date":" 11/01/2001","primary_txt":" Primary completion: 06/01/2005","primary_completion_date":" 06/01/2005","study_txt":" Completion: 06/01/2006","study_completion_date":" 06/01/2006","last_update_posted":"2023-11-03"},{"id":"6b48bb98-5d08-4277-87fc-9cbfba13b91d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00796068","created_at":"2021-01-18T03:01:17.895Z","updated_at":"2025-02-25T12:35:31.293Z","phase":"Phase 2","brief_title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematological Cancer Who Are Undergoing Umbilical Cord Blood Transplant","source_id_and_acronym":"NCT00796068","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • CD34 • HLA-B","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34 • HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • busulfan • Grafapex (treosulfan)"],"overall_status":"Completed","enrollment":" Enrollment 130","initiation":"Initiation: 02/24/2009","start_date":" 02/24/2009","primary_txt":" Primary completion: 12/14/2021","primary_completion_date":" 12/14/2021","study_txt":" Completion: 12/14/2021","study_completion_date":" 12/14/2021","last_update_posted":"2023-02-17"},{"id":"d1582dd1-e768-4f7e-b5d2-a0089b8a5d93","acronym":"","url":"https://clinicaltrials.gov/study/NCT00919503","created_at":"2021-01-18T03:33:26.727Z","updated_at":"2024-07-02T16:36:26.391Z","phase":"Phase 2","brief_title":"Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders","source_id_and_acronym":"NCT00919503","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["CD33 • HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e methotrexate • fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 98","initiation":"Initiation: 07/31/2009","start_date":" 07/31/2009","primary_txt":" Primary completion: 06/10/2020","primary_completion_date":" 06/10/2020","study_txt":" Completion: 06/10/2020","study_completion_date":" 06/10/2020","last_update_posted":"2021-08-13"},{"id":"1611432e-6e0a-4cd7-b5b1-2ffab38012c8","acronym":"","url":"https://clinicaltrials.gov/study/NCT00860574","created_at":"2021-01-18T03:16:53.510Z","updated_at":"2025-02-25T16:23:06.732Z","phase":"Phase 2","brief_title":"Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia","source_id_and_acronym":"NCT00860574","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • busulfan • Grafapex (treosulfan) • methotrexate IV"],"overall_status":"Completed","enrollment":" Enrollment 96","initiation":"Initiation: 02/01/2009","start_date":" 02/01/2009","primary_txt":" Primary completion: 02/01/2013","primary_completion_date":" 02/01/2013","study_txt":"","study_completion_date":"","last_update_posted":"2021-06-22"},{"id":"6e46ac0f-3099-474a-8dfb-83275c3a0b32","acronym":"","url":"https://clinicaltrials.gov/study/NCT01894477","created_at":"2021-01-18T08:31:16.616Z","updated_at":"2024-07-02T16:36:29.526Z","phase":"Phase 2","brief_title":"Treo/Flu/TBI With Donor Stem Cell Transplant for Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia","source_id_and_acronym":"NCT01894477","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-DQB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • busulfan • Grafapex (treosulfan)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 11/01/2013","start_date":" 11/01/2013","primary_txt":" Primary completion: 01/09/2017","primary_completion_date":" 01/09/2017","study_txt":" Completion: 06/01/2022","study_completion_date":" 06/01/2022","last_update_posted":"2021-06-03"},{"id":"591f8526-ce03-4da2-985b-c4d42f183ed9","acronym":"","url":"https://clinicaltrials.gov/study/NCT04000698","created_at":"2021-01-18T19:39:51.048Z","updated_at":"2024-07-02T16:36:38.415Z","phase":"Phase 3","brief_title":"Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Acute Leukemias","source_id_and_acronym":"NCT04000698","lead_sponsor":"Federal Research Institute of Pediatric Hematology, Oncology and Immunology","biomarkers":" BCL2 • CXCR4 • CD38","pipe":" | ","alterations":" CD38 expression • BCL2 expression","tags":["BCL2 • CXCR4 • CD38"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CD38 expression • BCL2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Venclexta (venetoclax) • cytarabine • Actemra IV (tocilizumab) • Grafapex (treosulfan) • Orencia (abatacept)"],"overall_status":"Recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 10/15/2019","start_date":" 10/15/2019","primary_txt":" Primary completion: 07/01/2022","primary_completion_date":" 07/01/2022","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-11-20"},{"id":"4bdccd3f-7393-41ae-be09-7346ea7310e5","acronym":"MC-FludT.14/L","url":"https://clinicaltrials.gov/study/NCT00822393","created_at":"2021-01-18T03:07:34.565Z","updated_at":"2024-07-02T16:36:42.573Z","phase":"Phase 3","brief_title":"Clinical Phase III Trial Treosulfan-based Conditioning Versus Reduced-intensity Conditioning (RIC)","source_id_and_acronym":"NCT00822393 - MC-FludT.14/L","lead_sponsor":"medac GmbH","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e busulfan • Grafapex (treosulfan)"],"overall_status":"Completed","enrollment":" Enrollment 570","initiation":"Initiation: 11/24/2008","start_date":" 11/24/2008","primary_txt":" Primary completion: 01/25/2018","primary_completion_date":" 01/25/2018","study_txt":" Completion: 01/25/2018","study_completion_date":" 01/25/2018","last_update_posted":"2020-07-30"},{"id":"c64d67d0-1d98-4279-bbe7-caeeb30cabc5","acronym":"","url":"https://clinicaltrials.gov/study/NCT02333058","created_at":"2021-01-18T11:04:36.347Z","updated_at":"2024-07-02T16:36:45.368Z","phase":"Phase 2","brief_title":"Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies","source_id_and_acronym":"NCT02333058","lead_sponsor":"medac GmbH","biomarkers":" HLA-DRB1","pipe":"","alterations":" ","tags":["HLA-DRB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Grafapex (treosulfan)"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 11/21/2014","start_date":" 11/21/2014","primary_txt":" Primary completion: 12/24/2016","primary_completion_date":" 12/24/2016","study_txt":" Completion: 09/30/2019","study_completion_date":" 09/30/2019","last_update_posted":"2020-05-04"},{"id":"4565cd60-700f-40d2-a4d5-801fe8a26059","acronym":"ModuLung","url":"https://clinicaltrials.gov/study/NCT02852083","created_at":"2021-01-18T13:59:56.649Z","updated_at":"2024-07-02T16:37:14.716Z","phase":"Phase 2","brief_title":"A Trial With Metronomic Low-dose Treosulfan, Pioglitazone and Clarithromycin Versus Standard Treatment in NSCLC","source_id_and_acronym":"NCT02852083 - ModuLung","lead_sponsor":"University Hospital Regensburg","biomarkers":" EGFR • ALK • PD-1 • RAS • PPARG • PPARA","pipe":"","alterations":" ","tags":["EGFR • ALK • PD-1 • RAS • PPARG • PPARA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Grafapex (treosulfan)"],"overall_status":"Unknown status","enrollment":" Enrollment 86","initiation":"Initiation: 01/01/2016","start_date":" 01/01/2016","primary_txt":" Primary completion: 07/01/2019","primary_completion_date":" 07/01/2019","study_txt":" Completion: 07/01/2020","study_completion_date":" 07/01/2020","last_update_posted":"2018-01-18"},{"id":"91067e53-7eb1-45f8-9e7a-325518bbb98c","acronym":"","url":"https://clinicaltrials.gov/study/NCT01772953","created_at":"2021-01-18T07:48:51.504Z","updated_at":"2024-07-02T16:37:28.533Z","phase":"Phase 2","brief_title":"Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT","source_id_and_acronym":"NCT01772953","lead_sponsor":"Center for International Blood and Marrow Transplant Research","biomarkers":" HLA-DRB1 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fludarabine IV • Grafapex (treosulfan)"],"overall_status":"Completed","enrollment":" Enrollment 40","initiation":"Initiation: 09/01/2013","start_date":" 09/01/2013","primary_txt":" Primary completion: 08/01/2015","primary_completion_date":" 08/01/2015","study_txt":" Completion: 08/01/2015","study_completion_date":" 08/01/2015","last_update_posted":"2016-10-12"},{"id":"d0499fed-ad0b-4aca-b121-2c23909688ba","acronym":"","url":"https://clinicaltrials.gov/study/NCT01079013","created_at":"2021-01-18T04:15:18.882Z","updated_at":"2024-07-02T16:37:32.614Z","phase":"Phase 2","brief_title":"Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies","source_id_and_acronym":"NCT01079013","lead_sponsor":"Sheba Medical Center","biomarkers":" HLA-DRB1 • CD34 • HLA-B • HLA-C","pipe":"","alterations":" ","tags":["HLA-DRB1 • CD34 • HLA-B • HLA-C"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • fludarabine IV • Grafapex (treosulfan)"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 04/01/2018","primary_completion_date":" 04/01/2018","study_txt":" Completion: 04/01/2018","study_completion_date":" 04/01/2018","last_update_posted":"2016-04-20"}]